AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05896969
Drug: SNK-396 - MAD Cohort
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple doses of SNK-396 within the dose range of from 25 to 800 mg, or matching placebo.
Trial: NCT05327855
Drug: OPL-0301 Dose 1
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
Trial: NCT05327855
Drug: OPL-0301 Dose 2
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
Trial: NCT05327855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
Trial: NCT04689347
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: leucovorin 200 mg/sqm intravenous infusion every 2 weeks
Trial: NCT04689347
Drug: 5Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 48-hours continuous intravenous infusion of 5-fluorouracil (5-FU) 3200 mg/sqm every 2 weeks
Trial: NCT05127473
Drug: Mim8 B, 10 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.
Trial: NCT05127473
Drug: Mim8 B, 100 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.
Trial: NCT05127473
Drug: Mim8 B, placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be used to dilute the IMP to different Mim8 concentrations
Trial: NCT06160414
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive Rosuvastatin orally, after fasting.
Trial: NCT06160414
Drug: ALXN2080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive ALXN2080 orally, after fasting.
Trial: NCT04601233
Drug: XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self injection testosterone treatment
Trial: NCT05557448
Drug: TYNADOTE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take 200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
Trial: NCT05557448
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take 200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
Trial: NCT05856513
Drug: ZSP1273
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive ZSP1273 orally.
Trial: NCT06329791
Drug: AZR-MD-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZR-MD-001 sterile ophthalmic ointment 0.5%
Trial: NCT05002686
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m\^2 orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
Trial: NCT04387734
Drug: Platform
RxNorm normalized name: Autolet Platform
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The applications of the platform DMTs will follow the FDA-approved regulations.
Trial: NCT06657105
Drug: EE/LNG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE/LNG tablet will be administered orally.
Trial: NCT04776499
Drug: Propylthiouracil, Riociguat, Perphenazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of propylthiouracil, riociguat, and perphenazine in combination~Investigational medicinal product (IMP):~Propylthiouracil: 100 mg, Riociguat: 1 mg, Perphenazine: 16 mg
Trial: NCT04714151
Drug: K-877 ER 0.2 mg/day (once daily)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-877 ER 0.2 mg tablet
Trial: NCT04714151
Drug: K-877 ER 0.4 mg/day (once daily)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-877 ER 0.4 mg tablet
Trial: NCT06289829
Drug: remifentanil of the assigned dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambu Auragain will be inserted after general anesthesia is induced with remimazolam and remifentanil. Each patient will be assigned with a certain dose of remifentanil, according to whether the previous patient's LMA insertion process was successful or not.
Trial: NCT06446310
Drug: QLG2198
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive QLG2198 three times a week (0,5 micrograms/kg dry body weight). QLG21988 is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
Trial: NCT06446310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive Placebo three times a week (0,5 micrograms/kg dry body weight). Placebo is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis
Trial: NCT04694612
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to placebo in the patients with mild COVID-19
Trial: NCT05118516
Drug: ASC43F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of oral ASC43F FDC tablet containing ASC41 5mg and ASC42 15mg.
Trial: NCT06494280
Drug: continuous epidural infusion
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the control group protocol for pain maintenance, i.e., 0.1% Bupivacaine and 2 μg/ml fentanyl as a continuous infusion per one hour, until the delivery is completed, and laceration is sutured. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study.
Trial: NCT06207123
Drug: LP-118
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LP-118 is an experimental anti-cancer drug that is currently being studied in clinical trials for multiple types of hematological cancers and solid tumors.
Trial: NCT06504901
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine: 1000mg/m2 bid po, d1-d14
Trial: NCT06207123
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate is a drug used to treat cancer of the blood, bone, lung, breast, head, and neck. It can also treat rheumatoid arthritis and psoriasis.
Trial: NCT05742919
Drug: NNC0194-0499
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single s.c. dose of 12 mg NNC0194-0499 on Day 1.
Trial: NCT05742919
Drug: NC0194-0499
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single s.c. dose of 96 mg NNC0194-0499 on Day 1.
Trial: NCT05009368
Drug: Drug: Treatment B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTL0902, single dose, daily, repeated oral administration for 7 days
Trial: NCT05009368
Drug: Drug: Treatment C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTL0901 and CTL0902, single dose, daily, repeated oral administration for 7 days
Trial: NCT00002262
Drug: Tumor Necrosis Factor
RxNorm normalized name: Tumor necrosis factor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04528199
Drug: [18F]FLOR (FC303) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 10 ±1 millicurie (mCi) of \[18F\]FLOR (FC303) injection followed by the PET/CT scan.
Trial: NCT04924374
Drug: anti PD1 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: anti PD1 therapy every 2-3 weeks
Trial: NCT02707926
Drug: Anti-HIV Agents
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy to treat HIV infection
Trial: NCT06126861
Drug: [14C]LP-168
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of 150 mg/100 μCi \[14C\] LP-168, orally suspension at fasted state
Trial: NCT04669288
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral azithromycin (12 mg/kg per day for 5 days)~Local investigational drug pharmacies will be provided with active study medication (azithromycin) from a central pharmacy. Azithromycin will be reconstituted with water at the local pharmacy, and will resemble placebo with regards to appearance, flavor, consistency and packaging.
Trial: NCT04669288
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo (12 mg/kg per day for 5 days)~Local investigational drug pharmacies will be provided with placebo from a central pharmacy. Placebo will be reconstituted with water at the local pharmacy, and will resemble azithromycin with regards to appearance, flavor, consistency and packaging.
Trial: NCT04588441
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine will be given like an inhaled asthma medication two times daily for one week (7 days). Treatment consists of 9 mg adenosine in 5ml normal saline (NS) administered over 5-10 min via an Aerogen™ nebulizer.
Trial: NCT06240689
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered intravenously on the first day of each cycle. 21 days per cycle.
Trial: NCT05016687
Drug: CUR-N399
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CUR-N399 will be administered as oral capsules.
Trial: NCT05016687
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules matching CUR-N399 will administered.
Trial: NCT06389006
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: According to body surface area,600mg/m2, intravenous infusion, D1, every 3 weeks , Every 6 weeks is a treatment cycle. A total of 12 weeks of treatment are performed
Trial: NCT06382311
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of Placebo are administered intramuscularly to participants in Phase 1 and Phase 2 Part A and 1 dose is administered to participants in Phase 2 Part B.
Trial: NCT05319834
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: group 2: oral placebo once daily at the same time with progesterone
Trial: NCT05893511
Drug: Antibiotics first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to antibiotics first would be given intravenous antibiotics 2nd generation cephalosporin or equivalent). Antibiotics would first be given parenterally and then switched to oral form when patient can tolerate diet or when sepsis subside. It will be continued for at least a total of 7 days.
Trial: NCT06616168
Drug: Antibiotic therapy after the results of antibiotic sensitivity test (Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin)
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy after the results of antibiotic sensitivity test. Aminoglycosides, Carbapenems, Cephalosporins, Fluoroquinolones, Oxazolidinones are used. Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin are used for the therapy.
Trial: NCT05015335
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX 10mg qw
Trial: NCT04736108
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg oral low dose prednisone, once daily
Trial: NCT05470933
Drug: WJ01075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase Ia: Dose Escalation Accelerated titration (the first two dose groups) and 3 + 3 combination (the subsequent dose group) were used for dose escalation.~Phase Ib: Dose Expansion and Cohort Expansion The actual dose, dosing schedule (including combination) and indication selection will be evaluated based on the results of existing trials.
Trial: NCT05131477
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Trial: NCT05125562
Drug: ExoFlo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to one of three infusions: (1) Normal Saline 100 mL, (2) Normal saline 90 mL and ExoFlo 10 mL, which is 7x1011 EVs, and (3) Normal saline 85 mL and ExoFlo 15 mL, which is 10.5x1011 EVs. The study intervention will only be dosed on day=1
Trial: NCT04845620
Drug: ARQ-151 Vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARQ-151 Cream - Vehicle
Trial: NCT06139055
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching-placebo oral tablets.
Trial: NCT06139055
Drug: Placebo (Capsule/Tablet)
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching-placebo oral capsules or tablets.
Trial: NCT05339646
Drug: SSD8432 dose 8~9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 4: SSD8432 dose 8 or placebo, on day 1 \~day6. Cohort 5: SSD8432 dose 9 or placebo, on day 1 \~day6.
Trial: NCT05122221
Drug: Fludarabine + Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine: 25mg/m²/day×3days Cyclophosphamide: 500mg/m²/day×3 days
Trial: NCT05420779
Drug: Investigator's choice of chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine tablets, 1250 mg/m2 each time, BID oral administration; Vinorelbine tartrate injection, 25 \~ 30 mg/m2 each time, intravenous drip (15 \~ 20 min); Eribulin mesylate injection, 1.4 mg/m2 each time, intravenous injection (2 \~ 5 min)
Trial: NCT06293326
Drug: bi-layer calcium carbonate tablet (BAY1180654)
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Singal dose; two tablets; administered 1-2 hours post standardized meal depending on day or night dosing.
Trial: NCT06293326
Drug: Immediate release calcium carbonate tablet (BAY1180654)
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Singal dose; two tablets; administered 1-2 hours post standardized meal depending on day or night dosing.
Trial: NCT05762484
Drug: Clindamycin 1 % Topical Lotion
RxNorm normalized name: clindamycin 1 % Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 1% lotion if needed
Trial: NCT05392374
Drug: ONC201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONC201 is an oral, small molecule selective antagonist of DRD2
Trial: NCT04669717
Drug: 1/d 500 mg Azithromycine Pfizer for 3 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal therapy and radnomly administration of the antibiotics
Trial: NCT05947370
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control
Trial: NCT05685277
Drug: Tritace® Plus tablet 10 mg/25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tritace® Plus is manufactured by Sanofi S.p.A., Italy (holder of the registration certificate: Sanofi-Aventis Deutschland GmbH, Germany). Each tablet contains 10 mg of ramipril and 25 mg of hydrochlorothiazide.
Trial: NCT05387148
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be identical in appearance, taste, and composition except for the active ingredient of pure CBD. So, four 200mg soft gel capsules of the placebo will be taken orally daily for a total of 3 days.
Trial: NCT05889234
Drug: Conventional pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pharmacotherapy: SSRIs including fluoxetine, paroxetine, sertraline, cetinopram, fluvoxamine, vortioxetine, escitalopram; SNRIs including venlafaxine, duloxetine; NaSSA including mirtazapine; other antidepressants including trazodone, bupropion, agomelatine; potentiators including aripiprazole, olanzapine, quetiapine, risperidone.
Trial: NCT05265819
Drug: thyroid hormone replacement therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT, THYROID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: thyroid hormone replacement therapy
Trial: NCT05266079
Drug: Intervention Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gan Mai Bai He Di Hung Tang, Tian Wang Bu Xin Dan,Shugan Granules,Liu Wei Di Huang Pill and Er Zhi Pill , You Gui pill and Li Zhong pill addition and subtraction
Trial: NCT05266079
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er-Xian decoction
Trial: NCT04094948
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dextrose-filled capsules
Trial: NCT04774341
Drug: anticoagulation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence to personalized evidence-based anticoagulant treatment in patients at high risk for stroke with atrial fibrillation
Trial: NCT04754334
Drug: ORMD-0801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Insulin
Trial: NCT05369078
Drug: THR-1442 20mg Multiple dose group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THR-1442 20mg is administrated QD for 7days, then follow till day 14.
Trial: NCT06504147
Drug: Radspherin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days.
Trial: NCT06148545
Drug: Elemental iron
RxNorm normalized name: Elemental Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A who received standard therapy (Fe preparations) 3 mg/kg BW/day
Trial: NCT06148545
Drug: Elemental iron and Vit D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B received standard therapy (Fe preparations) 3 mg/kgBW/day combination with vitamin D, 400IU).
Trial: NCT04681651
Drug: Normobaric Hyperoxia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Within 6 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
Trial: NCT00320567
Drug: norgestimate/ethinyl estradiol
RxNorm normalized name: Norgestimate/Ethinyl Estradiol 28-Day 0.215mg-0.025mg/0.25mg-0.025mg/0.18mg-0.025mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04711967
Drug: drug
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug
Trial: NCT02575508
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05774756
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to setmelanotide for daily subcutaneous injection
Trial: NCT04997395
Drug: MediCabilis Cannabis sativa 50
RxNorm normalized name: CANNABIS SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Already described
Trial: NCT04677855
Drug: PCUR-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg capsules
Trial: NCT05641051
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cases will receive the same volume of IV placebo / 6 hours.
Trial: NCT05545111
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching NBI-1117568
Trial: NCT05101369
Drug: INCB086550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB086550 will be administered orally, followed approximately 10 minutes later by an oral dose solution of radio labeled INCB086550.
Trial: NCT05724446
Drug: Prednisolone acetate ophthalmic suspension, 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microfine sterile ophthalmic suspension of dense and whitish appearance.
Trial: NCT06031129
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline contain 0.9% NaCl sodium.
Trial: NCT05470764
Drug: TRIPLIXAM® 10 mg /2.5 mg/10 mg, 10 mg perindopril arginine / 2.5 mg indapamide / 10 mg amlodipine film-coated tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, innovative fixed-dose combination of perindopril arginine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure), indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure) and amlodipine (calcium channel blocker used to treat high blood pressure and coronary artery disease).
Trial: NCT05919381
Drug: Gentuximab Injection Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentuximab Injection Placebo 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.